SARS-CoV-2 whole genome sequencing in SAB-185 for Non-hospitalized Adults with COVID-19
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1023880
下载链接
链接失效反馈官方服务：
资源简介：
The ACTIV-2/A5401 platform was designed to evaluate multiple investigational agents for outpatient COVID-19 treatment. For the phase 3 trial of SAB-185, participants were randomized 1:1 to open-label SAB-185 (3,840 units/kg) or casirivimab/imdevimab (600 mg/600 mg) given once by intravenous infusion.
创建时间：
2023-10-04
